aMoon
ACCELERATING CURE

2025 Impact Report

aMoon is a global HealthTech and Life Sciences investment fund headquartered in Israel on a mission to accelerate cure. With over $1.3B AUM, aMoon is Israel's largest VC fund dedicated solely to HealthTech. We partner with outstanding entrepreneurs who harness groundbreaking science and technology to create lifechanging solutions. Together with our portfolio companies, we work tirelessly to advance technologies that help people live longer, better, healthier lives.

Table of Contents

03 Managing Partners' Foreword

04 Impact Engine of HealthTech

08 aMoon in Numbers

14 Accelerating Cure
Our Impact Thesis

24 Responsible Investing
Our ESG Framework

26 Real People; Real Impact

31 Sourcing Engine

35 Venture Formation & Cross-Fund Synergies

39 Investor Additionality

41 Building & Nurturing a Global HealthTech Ecosystem

Managing Partners' Foreword

REAL PEOPLE; REAL IMPACT



Yair Schindel, MD, MBA



Tomer Berkovitz, PhD

As we present our sixth annual Impact Report, our focus this year reflects both our mission and how we measure success: real people, real impact.

At aMoon, this principle guides how we invest, build, and support companies. Behind every technology are individuals—patients, caregivers, and clinicians—whose lives are directly affected by the solutions we help bring to market. This perspective grounds our work and reinforces our belief that progress is only meaningful when it reaches people.

Over the past year, we have continued to partner with exceptional founders developing technologies that deliver tangible outcomes across the healthcare ecosystem. Our portfolio has shown strong momentum, with multiple companies completing significant funding rounds to accelerate growth, expanding access through increased policy coverage and covered lives, and launching new products into the market. These milestones reflect operational progress, as well as a growing ability to deliver real-world impact.

We have also seen the strength of our venture formation model in action. MetaSight's journey from inception to acquisition in only 4.5 years, demonstrates how focused execution and the right support can translate vision into solutions with the potential to affect millions of lives and significantly shorten time to value.

In a dynamic and ever more uncertain world, we have remained focused on long-term value creation. Despite a long and deep trough in global HealthTech markets, and ongoing geopolitical challenges, the resilience and adaptability demonstrated by our team and portfolio companies have been critical in sustaining progress and advancing our shared mission.

Ultimately, we measure success not only by innovation or scale, but by the extent to which our efforts translate into better care, improved access, and enhanced quality of life.

In the pages that follow, you will find examples of this impact and how we, together with our LPs, portfolio companies, and partners, are working to build a healthier future.

Thank you for being part of this journey.

With gratitude,

Yair & Tomer

Managing Partners, aMoon Fund




Chapter 01


Impact Engine of HealthTech

Major scientific breakthroughs in the last decade laid the foundations for a new era of innovation transforming the $10T global healthcare industry.
We are now beginning to see the impact of this transformation at scale

Improving the way we diagnose, treat, and cure diseases across the continuum of care



We Invest Across the Innovation Life



Israel is a Leading Global HealthTech & Innovation Hub



LEADING GLOBAL INNOVATION HUB

#1 IN THE WORLD IN RESEARCHERS PER CAPITA

TEL AVIV UNIVERSITY · TECHNION Israel Institute of Technology · BGU Ben-Gurion University of the Negev · WEIZMANN INSTITUTE OF SCIENCE · Bar-Ilan University · האוניברסיטה העברית בירושלים THE HEBREW UNIVERSITY OF JERUSALEM

LEADING INNOVATIVE HOSPITALS

RABIN MEDICAL CENTER BEILINSON • HASHARON · Hadassah University Hospital · RAMBAM Health Care Campus · SHEBA Tel HaShomer City of Health · ICHILOV TEL-AVIV SOURASKY MEDICAL CENTER MEDICAL EXCELLENCE AND COMPASSIONATE CARE

UNIQUE DATASETS, SCALABLE PLATFORMS

CENTRALIZED & DIGITIZED HEALTHCARE SYSTEM

CLALIT · Maccabi Healthcare Services · Leumit · MEUHEDET Setting a New Level of Healthcare

“START-UP NATION” LEADERSHIP IN DIGITAL TRANSFORMATION

WIZ · monday.com · CHECK POINT · WIX · waze



Chapter 02


aMoon in Numbers

Our HealthTech Investment Platform

2017
Founded

$1.3B
AUM

40+
Active Portfolio Companies



2
aMoon Locations
Ra'anana, Israel | Boston, MA



35+
Team Members

8
Co-Investments



4
Investment Vehicles
- Velocity
- Growth I
- Growth II
- Edge

Dedicated Platform
aMoon Alpha, IR & Communications, Finance & Operations, Legal, Compliance

120+
Global Limited Partners

aMoon Portfolio

We are proud to partner with innovators at the cutting edge of biology and technology, across HealthTech sectors, stages and geographies.

DIGITAL HEALTH & TECH ENABLED SERVICES

air doctor
Better Life PARTNERS ** ACQ by GRT
Breeqt
connie health
eleos
GraphiteRx
Hopscotch Primary Care
IBEX
lin
Lyfegen
MDCLONE
omada NASDAQ:OMDA
positive development
SOPHiA™ NASDAQ:SOPH
zebra MEDICAL.VISION M&A | Exit

MEDTECH, TOOLS & DIAGNOSTICS

AKOYA BIOSCIENCES NASDAQ:QTRX
CartiHeal M&A | Exit
iantrek
MAGENTIQ EYE
METASIGHT M&A | Exit
MOBILion SYSTEMS, INC.
prognomiQ
seer NASDAQ:SEER
SERA PROGNOSTICS The Pregnancy Company NASDAQ:SERA
theranica
ULTIMA GENOMICS

THERAPEUTICS

ADCYTHERIX
Adicet Bio NASDAQ:ACET
ALTRUBIO
BiolojicDesign
cavos validated by nature
Coltac Therapeutics
character
LUTRIS
MiNA Therapeutics
NECTINTx
Pacegenix *
Plexium
Satellite BIO
scipher MEDICINE

* Investment completed in Q1 2026
** Merged with Groups Recover Together in Q1 2026

aMoon Culture & Mindset

We are a team of scientists, physicians, entrepreneurs, and investors with global experience who work to advance solutions that will help people live healthier, better lives.

We firmly believe collaboration among team members with a wide range of experiences generates more incisive and deeper insights that better serve our investors, portfolio companies and community.

Our commitment to these values is central to our core mission to accelerate cure. We recognize the value of varied perspectives in solving complex problems in a changing-and increasingly diverse world.


We aim to fulfill the following objectives to unleash the potential of a dedicated and committed mix of people:

Enhance employee engagement and collaboration


Recruit, develop and retain talented employees from all backgrounds and experiences

Expand our impact and community engagement across HealthTech hubs around the globe

WORK EXPERIENCE



EDUCATION




LANGUAGE & CULTURE

78% have lived, worked, or studied in 2+ countries

12 Nationalities

19 Average years of education




Our 2025 Investments

$53.4 million

This past year, we invested in 7 new exciting companies and continued to support 8 of our existing portfolio companies with additional investments as they progressed toward major milestones in their journey to accelerating cure.

Follow-on Investments




















New Investments















Together with Our Co-Investors, our Global Impact Reaches Even Further

$3.5 billion

Was raised by our portfolio companies as in public and private rounds during and after our initial investment, through the end of 2025




Chapter 03

Accelerating Cure

Our Impact Thesis

At aMoon, we believe that creating long-lasting impact and sustainable value is deeply connected to our ability to advance technologies that help people live healthier, longer, and better lives.



Impact Pillars

We believe everyone deserves better access to better healthcare.

We work to identify and fund transformative solutions that tackle healthcare's most pressing challenges while simultaneously producing value for our stakeholders.

Our impact assessment manifests across the entire investment cycle; from screening, through investing, to monitoring our portfolio.

We have defined five impact pillars that derive from our mission to accelerate cure:

Save & extend lives

We back innovations that can cure diseases and save lives through breakthrough treatment mechanisms.

Improve quality of life

We don't just aim to keep people alive longer, but also to improve the quality of life for those with acute or chronic diseases.

Increase access to care

We support solutions aiming to democratize healthcare and ensure access to affordable, quality health services for all.

Reduce costs


As healthcare costs rise to unsustainable levels, we focus on technologies that increase institutions' capacity and cut costs.

Enable breakthrough discoveries

We promote the development of groundbreaking technologies that transform the way we diagnose and treat disease.

Innovation Index

VELOCITY



Innovation Index

GROWTH I

COMPANY	SAVE & EXTEND LIVES	IMPROVE QUALITY OF LIFE	INCREASE ACCESS TO CARE	REDUCE COSTS	ENABLE SCIENTIFIC BREAKTHROUGHS
ALTRUBIO	■	■		■	■
BiolojicDesign	■	■			■
KHR	■				
MDCLONE	■	■	■	■	■
MiNA Therapeutics	■				■
MOBILion SYSTEMS, INC.					■
omada		■	■	■	
prognomiQ	■			■	
Satellite BIO	■	■			■
scipher MEDICINE	■	■	■	■	■
seer	■				■
SERA PROGNOSTICS	■	■	■	■	■
SOPHiA GENETICS			■	■	■
theranica		■	■	■	
ULTIMA GENOMICS	■	■	■	■	■

Innovation Index

GROWTH I

COMPANY	SAVE & EXTEND LIVES	IMPROVE QUALITY OF LIFE	INCREASE ACCESS TO CARE	REDUCE COSTS	ENABLE SCIENTIFIC BREAKTHROUGHS
Air Doctor		■	■	■	
ADCYTHERIX	■	■			■
Better Life Partners	■	■	■	■	
character		■			■
connie health		■	■	■	
Hopscotch Primary Care	■	■	■	■	
iantrek			■	■	
METASIGHT	■	■		■	■
omada		■	■	■	
Plexium	■	■			■
positive development		■	■	■	

Breeoot

UNLEASHING THE POWER OF INNOVATION FOR PERSONALIZED HEALTHCARE EXCELLENCE

Today's healthcare systems are notoriously reactive, fragmented, and heavily burdensome for patients. Breeoot, a modern, AI agent-enabled health clinic focused on preventative, proactive, and personalized primary care redefines what healthcare can do by harnessing a tech-driven approach to health management aiming to extend and enhance health span – the number of healthy, active years in an individuals' life.

At the heart of Breeoot's offering is a sophisticated agentic AI platform that analyzes patient data to surface actionable clinical insights and recommend optimal treatment strategies. This tech backbone is complemented by a dedicated multidisciplinary care team assigned to each patient, providing ongoing support. This combination of AI-driven precision with human expertise offers customers an elevated, tailored healthcare experience.

What sets Breeoot apart is not just the high-quality service, but its scalability and vision. The internal platform unifies data and clinical expertise into a cohesive system that can be adapted and scaled globally.

Ultimately, Breeoot seeks to transform the very idea of what healthcare can and should be, representing a fundamental shift from reactive medicine to proactive health management which will extend life and improve quality of life.

SAVE & EXTEND LIFE

80%

OF FIRST CARDIAC EVENTS OCCUR IN PATIENTS WITH NORMAL CHOLESTEROL RESULTS

12+

SPECIALISTS COORDINATED AS ONE CLINICAL TEAM



300+

BIOMARKERS TRACKED ACROSS ALL SYSTEMS

UP TO 80%

OF PREMATURE DEATHS ARE PREVENTABLE WITH EARLY INTERVENTION

character

TRANSFORMING EYE CARE WITH PRECISION MEDICINE

For decades, scientists and clinicians have struggled with a frustrating reality: patients diagnosed with the same disease often experience vastly different outcomes. Nowhere is this more evident than in age-related macular degeneration (AMD), a leading cause of blindness, where some patients decline rapidly while others progress slowly or not at all.

As researchers explored this variability, they realized that many chronic diseases are not driven by a single cause, but by complex combinations of genetic and biological factors. Yet despite this complexity, most treatments have remained one-size-fits-all, failing to address the underlying drivers of disease for individual patients.

Character Biosciences was founded to change this paradigm. By combining large-scale clinical data, human genetics, and computational biology, the company is working to decode the patterns behind complex, polygenic diseases and develop targeted therapies tailored to specific patient populations.

Starting with AMD, Character is building a new model for drug discovery, one that identifies the biological pathways driving disease progression and matches them with precision treatments. Their approach has the potential to transform how conditions like AMD and glaucoma are treated, moving away from generalized therapies toward personalized care.

For patients, the impact could be profound. Instead of facing uncertainty and decline, individuals at risk of vision loss may receive treatments designed specifically for their disease profile, preserving sight, independence, and quality of life for millions affected by degenerative eye diseases.

IMPROVING QUALITY OF LIFE

1 in 8

PEOPLE OVER THE AGE OF 50 ARE IMPACTED BY AMD

>80%

OF CHRONIC DISEASE ARE POLYGENIC



LEADING CAUSE

OF BLINDNESS IN PEOPLE OVER 60

4

PROGRAMS IN CHARACTER'S PIPELINE

air doctor

EASILY ACCESS MEDICAL CARE ABROAD

INCREASE ACCESS TO CARE

While on a trip to South America in 2014, Yam Derfler, Co-Founder of Air Doctor, fell ill and was treated at a local hospital. The long hours spent in the hospital, in addition to, poor treatment led Yam to realize that there had to be a better solution for travelers unfamiliar with local medical services.

A quick survey showed that most of his traveler friends who fell ill or were injured preferred to wait it out rather than see a doctor due to a lack of trust in the local health services.

Upon his return, Yam decided to research this experience and concluded that this happens far too often. No one should have to be in a situation where they put their health at risk, especially when traveling abroad.

Air Doctor was created to give travelers an intuitive and accessible platform to find the right doctor for their needs, wherever they might be. The platform helps travelers find local doctors and specialists who speak their language while abroad, ensuring customers get quality medical care, wherever they are.

With a network of thousands of trusted licensed medical professionals in countries across Europe, Asia, Australia and America, Air Doctor delivers a new standard of care to its customers.

OPERATES IN
35+
COUNTRIES

USED BY
2,000
DOCTORS AROUND THE WORLD



24/7
AVAILABILITY

5+
SPECIALTIES PER CITY

eleos

AI-POWERED BEHAVIORAL HEALTHCARE

While working closely with behavioral health providers, the founders of Eleos Health saw a troubling pattern: clinicians were overwhelmed with administrative work, often spending as much time documenting sessions as they did actually treating patients. This burden not only led to burnout among providers but also reduced the quality and consistency of care patients received, while driving inefficiencies and unnecessary costs across the health system.

As they dug deeper, it became clear that behavioral health care systems were struggling to scale, even as demand surged globally. Therapists lacked the tools to easily capture insights, track progress, and ensure best practices across sessions. In a field where every conversation matters, too much critical information was being lost or underutilized, impacting both clinical outcomes and the financial sustainability of care delivery.


Determined to address this gap, Eleos Health was founded to bring the power of AI into the therapy room, supporting clinicians behind the scenes. The platform analyzes sessions, automates documentation, and surfaces real-time insights, dramatically reducing time spent on administrative tasks. By accelerating documentation workflows, Eleos helps organizations lower operational costs while improving revenue cycle performance, supported by the fact that 90% of Eleos-generated notes are submitted within 24 hours, reducing the risk of claim denials due to late submission.

Today, Eleos Health is helping behavioral health organizations deliver more consistent, data-driven care at scale. By reducing clinician burnout, improving treatment quality, and enhancing financial efficiency, the company is having a direct impact on both providers and patients—ensuring that more individuals receive timely, effective support during some of the most vulnerable moments of their lives.

REDUCE COSTS

REDUCES DOCUMENTATION TIME BY
>70%

WORKS IN
100+
LANGUAGES



90%
OF ELEOS-GENERATED NOTES ARE SUBMITTED WITHIN 24 HOURS

PROVIDERS ACCEPT
80%
OF ELEOS SUGGESTIONS

SOPHiA™

ENABLE SCIENTIFIC BREAKTHROUGHS

DEMOCRATIZING DATA-DRIVEN MEDICINE

SOPHiA GENETICS is focused on advancing precision medicine through artificial intelligence and data analytics. With its proprietary DDM™ (Data-Driven Medicine) platform, SOPHiA helps hospitals, laboratories, and biopharmaceutical companies transform complex health data into actionable clinical insights by analyzing genomic, radiomic, and other multimodal health data. SOPHiA enables healthcare providers to make more informed decisions for patients with cancer, rare diseases, and inherited disorders.


At the core of the company's approach is the belief that healthcare data becomes more valuable when it is analyzed collectively. The SOPHiA DDM™ platform leverages AI and ML to identify clinically relevant patterns across millions of patient profiles, helping clinicians interpret complex diagnostic results more accurately and efficiently. The platform continuously learns from a global network of healthcare institutions, creating a powerful feedback loop that improves performance over time while maintaining strict standards for data privacy and security.

SOPHiA supports a network of almost 1,000 healthcare institutions across more than 70 countries and has analyzed over two million genomic profiles. Its technology is used to streamline diagnostic workflows, accelerate turnaround times, standardize genomic interpretation, and expand access to advanced precision medicine capabilities worldwide. The company's solutions help healthcare organizations navigate the growing complexity of genomic testing and clinical data, enabling more personalized approaches to diagnosis and treatment.

Beyond clinical diagnostics, SOPHiA collaborates with leading research institutions, healthcare systems, and pharmaceutical companies to advance oncology research, clinical trials, and next-gen therapeutic development. Through its combination of AI, large-scale real-world data, and global clinical collaboration, SOPHiA is helping drive a future in which more patients benefit from faster diagnoses, more targeted therapies, and better health outcomes.

OPERATES IN
990+
HEALTHCARE INSTITUTIONS

OPERATES IN
75+
COUNTRIES



2.3M+
GENETIC PROFILES ANALYZED

ANALYZES MULTIPLE HEALTH DATA SETS WITH
99%
ACCURACY



Chapter 04

Responsible Investing

Our ESG Framework

Integrating ESG into our practices & Investment Lifecycle

Striving for continuous improvement

At aMoon, we seek to integrate environmental, social, and governance (ESG) considerations into our daily operations as well as into our investment process in line with industry guidance and best practice standards. By examining the policies and practices of potential portfolio companies to adhere to these values, we maximize impact while mitigating risk.

We also monitor our portfolio companies ESG progress to identify gaps and value creation opportunities. Our dedicated team is available to work with each company to improve ESG adherence.

As a signatory to the UN Principles of Responsible Investing (PRI), the largest global reporting project on responsible investment, we put responsible investing into practice and contribute to the development of a more sustainable global order.

The 2024 Impact Report included a comprehensive survey of our portfolio companies that we undertake every other year. Using the results from the survey, we identify opportunities to drive improvements within the companies to improve ESG focus.

ENVIRONMENT

- Environmental impact
- Climate change & business
- Model resilience

SOCIAL

- Diversity & inclusion
- Human Capital development & corporate culture

GOVERNANCE

- Corporate governance
- Board governance
- Cyber & data privacy



Chapter 05

Real People; Real Impact

Meet some of the people whose lives and work have been positively impacted by our portfolio companies' innovations

eleos



For **Sherri**, a **Chief Clinical Officer in NYC**, the growing gap between client needs and staff capacity has become one of the most pressing challenges in behavioral health care. New clinicians are entering the workforce with varying levels of experience, while client needs continue to increase - placing additional strain on already stretched teams.

At the same time, administrative demands, particularly documentation requirements, have made it even harder for clinicians to focus on care.

“We were seeing clinicians spend 15 to 20 minutes per progress note,” she shared. “Now we’re seeing notes completed in about six to ten minutes - cutting that time in half.”

After implementing Eleos, the organization saw immediate improvements in efficiency. Clinicians gained back hours previously spent on documentation—reducing after-hours work and allowing them to better manage their time and well-being.

“It shaved off two to three hours of work for me,” one clinician noted. Beyond time savings, the platform also supported clinical quality. Staff reported that it helped them better connect conversations with clients to the clinical skills they were applying, strengthening the care they deliver.

Since adopting the technology, the organization has seen broader impact:
Improved staff retention and increased ability to recruit new clinicians; Higher client attendance at appointments; Stronger clinical outcomes.

“It has paid us back,” Sherri said. “The benefits far outweigh the cost—it’s a no-brainer.”

Watch Sherri’s story **here**

omada



As **Mike** took on more responsibility at work and home, he began experiencing atrial fibrillation and recognized the need to prioritize his health. He chose to get a pacemaker, with led to a host of health issues.

While he had tried other digital health programs before, he had found them impersonal and difficult to stick with. With Omada, that experience was different. Daily reminders encouraged him to check in on his health for just a few minutes at a time—but it was the human connection that made the biggest impact.

“The personal touch of my coach Leanne… she was in it for more than just another client check.”

Through consistent support and guidance, Mike began to build trust in the process. Over time, he made meaningful changes to his nutrition habits, including how and where he sources protein.

Those changes helped shift his overall approach to health.

“I went from somebody who was very unhealthy… to someone whose health is in the forefront.”

Today, Mike says the impact has been profound.

“My quality of life has improved beyond anything I could measure.”

“My quality of life has improved beyond anything I could measure.”

Omada continues to expand its approach to cardiometabolic health. Building on the success of its prevention and high blood pressure programs, the introduction of a cholesterol program brings together coaching, content, and digital tools into a more integrated experience.

Watch Mike’s story **here**

iantrek



As a glaucoma speci alist in private practice in Atlanta, **Dr. Arkadiy Yadgarov** has seen firsthand how treatment for glaucoma is evolving.

Historically, surgery was considered a last resort due to the risk of adverse effects. But in recent years, the rise of minimally invasive procedures has begun to shift that paradigm.

“That’s what’s exciting about glaucoma care now—learning how to use these safer interventions earlier,” he explained.

One of the ongoing challenges in glaucoma treatment is that many patients do not have a well-functioning trabecular outflow system, limiting the effectiveness of traditional approaches. For Dr. Yadgarov, the ability to access an alternative pathway has been a critical advancement.

“With AlloFlo, we finally have a way to utilize the uveoscleral outflow,” he said, describing it as a powerful and previously underutilized mechanism for lowering intraocular pressure.

In his experience performing dozens of procedures, Dr. Yadgarov has found the approach to be both safe and effective, without observing serious adverse effects.

“It’s a much-needed tool to treat patients,” he noted.

For Dr. Yadgarov, the significance lies not just in incremental improvement, but in opening an entirely new pathway for care—expanding what’s possible for patients with glaucoma.

“What’s most exciting... is that it’s a completely new pathway of treatment.”

Watch Arkadiy’s testimonial **here**

SERA™ The Pregnancy Company®



At 24 weeks pregnant, **Jackie** began experiencing early uterine contractions and was admitted to labor and delivery for several days.

With the PreTRM test providing an early data point, her care team recognized that she was at increased risk—allowing them to respond quickly and adjust her care.

“They worked around the clock to help figure out a way to stop my uterine contractions,” Jackie shared.

With that coordinated effort, Jackie was able to carry her baby, Ethan, to full term.

The PreTRM test is a simple blood test designed to identify mothers at higher risk of preterm birth earlier in pregnancy—even in cases where traditional risk factors may not indicate concern.

By providing clearer insight into risk, it enables physicians to take proactive steps to prolong pregnancy and improve outcomes for both mother and baby.

For many pregnancies, where risk is otherwise unknown, this kind of early detection can make a critical difference.

For Jackie, having that information early mattered.

“It’s a small test—it’s easy, it was fast, it was quick.”

Her experience highlights how earlier insight and proactive care can help change the course of a pregnancy - and support healthier outcomes for families.

Watch Jackie’s story **here**

conniehealth



When Terry and Darren turned 64, they began seriously exploring their Medicare options but quickly found themselves overwhelmed by constant mail and phone calls.

What they needed was clear: someone to sit down with them and guide them through the process step by step.

That's exactly what they found with Connie Health.

When Terry and Darren turned 64, they began seriously exploring their Medicare options but quickly found themselves overwhelmed by constant mail and phone calls.

What they needed was clear: someone to sit down with them and guide them through the process step by step.

That's exactly what they found with Connie Health. Through in-person support, they were able to understand the full process and felt confident knowing they would receive help at every stage. Their advisor, Rita, took the time to learn their needs and clearly explained the differences between Medicare plans and how each option would impact them long term.

"Rita was very transparent with us right from the very beginning," Terry shared. "Once she understood what we needed, she could tell us what would fit our needs best."
They were surprised by the level of personalized attention—especially since it came at no out-of-pocket cost. The team's responsiveness also stood out, with quick callbacks, regular emails, and availability by text.
For Terry and Darren, the experience felt less like a transaction and more like a trusted advisory relationship - one that made a complex decision far more manageable.

Watch Terry and Darren's story **here**

lin



Chronic pain had taken over Mitzi's life. Activities she once loved like hiking and yoga were no longer possible, and despite trying physical therapy, massage, and injections, nothing brought lasting relief.

"There were some days I really didn't believe that I would find my way back," she shared.

After years of limited progress, Mitzi was not expecting a new approach to make a difference. But when her doctor recommended Lin Health, she decided to try.

Mitzi was quickly connected with a pain coach and through one-on-one support, was able to understand how pain had impacted her physically, mentally, and emotionally. Early on, she learned about the brain-body connection and how it could be contributing to her pain. Using a range of evidence-based tools and techniques, she began building skills to better manage it.

Within just a few sessions, Mitzi noticed meaningful progress.

"I really felt like I had control of how to manage my pain," she said. "That gave me a lot of confidence to start doing the things I wanted to do again."

Ongoing access to her coach, including support via text between sessions, helped her navigate flare-ups and build confidence knowing she had expert guidance when she needed it.

Over time, Mitzi didn't just learn to manage her pain, she experienced long periods without it. After starting the program, she was able to walk down the aisle at her wedding pain-free and return to hiking in the woods for the first time in years.
"I really got my life back in a way that I never imagined that I would."

Watch Mitzi's story here

Hopscotch Primary Care



When **Frank** was diagnosed with stage 4 kidney failure, he needed coordinated, attentive care.

With Hopscotch Primary Care, he found a team that took the time to listen and understand his situation.

“They sat down, listened to me. They tried to understand the problems that I have,” Frank shared.

His care team worked closely together—coordinating with specialists, communicating directly, and aligning on a clear plan. They compared notes, stayed in sync, and ensured everyone was working toward the same goals.

“They were on the same page instead of one trying to get ahead of the other.”
With a structured approach that included diet, medication, and ongoing collaboration, Frank began to see meaningful progress.

“They have got me back to stage two.”

For Frank, the difference wasn’t just in the outcome—it was in how the care was delivered.

“They sit there with each other and then they talk to me... Somebody’s listening to what I’ve got to say. That makes a world of difference.”

Watch Frank’s story **here**

theranica



For **Molly**, a student, managing migraines used to mean frequent disruptions to daily life—often requiring leaving school early when treatments didn’t work.

She had tried multiple options, including injections, nerve blocks, and nasal sprays, but found that relief was either short-lived, ineffective, or came with side effects.

Now, she use Nerivio, a portable device she carries with her throughout the day.


“I just keep it with me everywhere—at school, I can put it on my arm and keep working,” she shared.

Unlike previous treatments that required hospital visits, the device can be used quickly and discreetly, connecting in under a minute without interrupting their routine.

Since using it, Molly has seen a noticeable improvement.
“It really helps. I still have migraines, but they’re not as extreme as they used to be.”

With easier access to relief, they’re able to stay in school and continue their day with fewer disruptions.

Watch Molly’s story **here**



Chapter 06

Sourcing Engine

Our Investment Sourcing Engine

Extensive footprint in Israel and strong global network generating almost 10,000 investment opportunities since inception

- Proactive & reactive deal flow
- Referrals from global network of venture partners and advisors
- Entrepreneur In Residence (EIR) Program
- High quality syndication opportunities from top international funds
- Collaborations With Major Pharma, Strategics & Academic Institutions

STARFINDER LAB
In partnership with Roche

bina בינה | SHEBA Tel HaShomer City of Health | MERCK
WEIZMANN INSTITUTE OF SCIENCE

LEAP
In partnership with
Medtronic | Microsoft | 8200 Bio | NVIDIA | BMC Innovation


WEHI brighter together




aMoon Deal Flow Funnel

2019 – 2025


Velocity Deal Flow Funnel




Growth Deal Flow Funnel




Deal Flow Segmentation by Geography





Deal Flow Segmentation by Sector



Chapter 07

Venture Formation & Cross-Fund Synergies

Demonstrated Track Record in Venture Formation

aMoon builds companies around groundbreaking platform technologies.

We identify these technologies through proactive engagement with leading research and tech centers and provide them with critical support services including talent placement, fundraising, and strategy.

Breeet

A modern health clinic focused on preventative, proactive, and personalized primary care

cavos
validated by nature

Proprietary comparative genomics algorithms to discover and develop novel mRNA therapeutics for cancer and other diseases

Coltac Therapeutics

A cost-effective, positive signal, e. coli-based system to discover and develop novel molecular glues for targeted protein degradation

lin

The first truly digital pain care clinic enabling remote care

METASIGHT

Multi-omic diagnostic tests for various diseases discovered using proprietary, unbiased, high throughput Mass Spec analyses of a population-scale biobank

NECTINTx

Biopharmaceutical company developing multiple first- and best-in-class immune checkpoint inhibitors and ADCs

Satellite BIO

Implantable satellite matrices as living therapeutic solutions for patients who suffer from serious liver diseases

METASIGHT

Case Study: From Venture Formation to Exit

A Velocity Venture Formation led to a Growth II Investment followed by a successful exit for both funds in under 5 years

2021

Sourcing & Transaction with TTO

Prof. Tomer Shlomi from **Technion** approaches Yaron via colleague **referral** resulting in aMoon Velocity **Venture Formation**

2022

Team Building

Placement of **key team members** who joined the MetaSight team

2023

Storytelling & Marketing

Supporting **de-stealthing strategy** & crystallizing **messaging** and marketing materials

2024

Science

Strategic prioritization of company pipeline through extensive KOL engagement

2025

Strategic Planning

Secured **exclusive contract for clinical data and samples** with Israel's second largest HMO

Business Development

Discovery partnerships with **TEVA** & **Roche Diagnostics**

Series A Fundraising

Introductions to **~90 investors** across aMoon's network, yielding oversubscribed **Series A**

Strategic Partnerships

aMoon introduced MetaSight to global **diagnostic strategics**, leading to multiple pilots

2026

Up to $150M Acquisition by Guardant Health

Led **M&A negotiations** leading to **optimized outcome** for MetaSight Shareholders and aMoon LPs

METASIGHT

ACCURATE, AFFORDABLE, AND ACCESSIBLE DIAGNOSTICS WITH A SINGLE BLOOD TEST

MetaSight pioneered the development of accurate, affordable, and accessible disease diagnostics and monitoring through advanced blood testing, designed for high-volume population-scale screening.

Founded in 2020 as a Venture Formation collaboration between aMoon Velocity and Prof. Tomer Shlomi, a computational biology professor from the Technion (Israel Institute of Technology), MetaSight leveraged Israel's centralized healthcare system by partnering with Israel's second largest HMO, Maccabi Healthcare Services. MetaSight and Maccabi established the world's largest blood-molecule database. This integrated discovery platform enables breakthroughs in multi-disease detection and monitoring, unlocking early and accurate diagnostic capabilities at unparalleled scale and significantly lower cost.

Harnessing the power of multi-omics and longitudinal health data, the company developed advanced blood-based diagnostics designed to be accurate, affordable, and scalable across large populations.

At the intersection of data science and biology, MetaSight's platform integrates complex molecular signals to enable earlier detection and deeper insights into disease progression. Guided by strong clinical and strategic leadership, including Dr. Yaron Daniely as Chairman of the Board, the company built a foundation of scientific rigor and real-world applicability.

MetaSight's impact and innovation culminated in its acquisition by Guardant Health, a leading U.S.-based liquid biopsy company, for up to $150 million. With research and operations remaining in Israel, MetaSight continues to contribute to the advancement of next-generation diagnostics, helping pave the way for more proactive, accessible, and data-driven healthcare.





Chapter 08

Investor Additionality

2025 Investor Additionality Spotlight

Capital

positive development

aMoon maintains active connections with **160+ funds internationally**, which are leveraged to assist our portfolio's fundraising and to further enrich our funds' pipelines.

Introduced Positive Development to **5 debt funds**

K2 Health Ventures & Trinity Capital submitted term sheets

Strategic Partnerships



Identified **Keen Insurance Services** as a strategic fit to accelerate Connie Health's growth, and facilitated an introduction

The connection culminated in Connie Health's **acquisition of Keen Insurance Services**

Strengthened Connie Health's commitment to **expanding** its reach and helping seniors across the U.S. make informed healthcare decisions

Science

caVos
validated by nature

Introduced **three leading scientific experts** relevant to caVos's research and development

All of these advisors now play a key role in guiding caVos's **strategy and execution** at its pre-clinical stage, strengthening the company's scientific and strategic foundation

Talent Acquisition



KAHR Bio was searching for an experienced, **Australian-based Board Member** for guidance in running clinical trials.

aMoon introduced **five candidates** with deep oncology drug development and corporate governance experience

Dr. Charmine Gittleson was chosen and has since joined the board of directors

Storytelling



Lin Health announced an **$11 million financing round**

As an active partner in the round, aMoon supported Lin Health beyond capital, working closely with the team to **refine the PR narrative and positioning**, and facilitating strategic media outreach by connecting the company with key contacts, including at Globes

Chapter 09


Building & Nurturing a Global HealthTech Ecosystem

Collaborations & Partnerships



8400 THE HEALTH NETWORK

8400 pioneers a powerful network of 2000+ Israeli ecosystem leaders & innovators across sectors to build the Israeli HealthTech powerhouse. aMoon takes an active role through sponsorship, leadership & participation in strategic ecosystem collaborations.




WEHI brighter together

The Innovation Fellows Program, held in collaboration with The WEHI Institute in Australia, aims to accelerate the translation of breakthrough academic research into impactful, real-world healthcare solutions. Along with leading academic institutions, the semi-virtual program combines bi-weekly sessions, mentorship from aMoon's expert team, and an in-person workshop and venture competition. Participants gain hands-on experience in evaluating academic technologies, building development and business plans, assessing IP and market potential, and understanding venture formation.



Entrepreneur in Residence ("EIR") Program

Our EIR program selects a small number of seasoned entrepreneurs every year for a six-month residency period. During that time, we provide them with access to the Fund's diverse activities, from deal flow meetings to diligence sessions and weekly portfolio reviews. We also help connect them with experts in our network. We work with them as they explore different ideas for new ventures and may ultimately choose to invest if they pursue a new venture that is aligned with aMoon's strategy.



LEAP

Medtronic · Microsoft · 8200Bio · BMC Innovation Bellinson Future of Health · NVIDIA

LEAP is a first-of-its-kind ideation program that brings together clinicians, tech talent, entrepreneurs and scientific researchers to answer unmet clinical needs with innovative solutions. This year, the focus was Bio-convergence technologies, merging engineering and life sciences to address industry challenges.

The 16-week program creates top-tier, multidisciplinary teams of entrepreneurs and physicians to explore and create revolutionary solutions to unmet needs in the healthcare ecosystem.

Connecting HealthTech Innovators Globally

2025 Events Timeline

Cracking the Healthcare Code



Specialty Care Event



BioMed




BIO



JournEY




HLTH



Q1 | **Q2** | **Q3** | **Q4**

JP Morgan




SPARC



LEAP



Teva Open Innovation



Innovation Fellows Program



BIO-Europe



Portfolio Companies in the News

NeurologyLive theranica

Anthem Blue Cross Blue Shield Expands Policy Coverage to Include **Nerivio** Migraine Treatment

READ MORE

FIERCE Biotech eleos

Behavioral health tech company **Eleos Health** raises $60M series C, launches compliance product

READ MORE

MEDTECHDIVE METASIGHT

Guardant buys **MetaSight** for $59M upfront to acquire blood test tech (2026)

READ MORE





FIERCE Biotech SOPHiA GENETICS™

Sophia Genetics unveils 'digital twins' tech to personalize cancer treatment

READ MORE



mobihealthnews lin

Exclusive: **Lin Health** raises $11M to scale digital chronic pain care

READ MORE

MedCity News character

Seeing a Better Way for Eye Drug R&D, **Character Bio** Lands $93M for Two Trials in Dry AMD

READ MORE



Healio iantrek

Iantrek launches AlloFlo Uveo for glaucoma treatment

READ MORE



Disclaimer

This presentation (including all information contained herein) is being delivered to parties for the purposes of learning about aMoon's impact. It is provided on a confidential basis to allow readers to learn more about aMoon (the "Fund").

This presentation is being provided to you for the sole purpose of affording you with background information about the Fund's business. Neither the presentation nor anything contained herein forms the basis of any contract or commitment. This presentation does not purport to be all-inclusive or to contain all the information that a prospective investor may desire in investigating the Fund. This presentation does not purport to summarize all of the conditions, risks, and other attributes of an investment in the Fund and is qualified in its entirety by the information to be made available by the Fund to persons meeting certain investment criteria and not to the public in general.

It is hereby clarified that the offering of interests in the Fund is a private offering and does not constitute and is not intended to constitute an "offer to the public" as defined in the Israeli Securities Law 5729-1968 (the "Israeli Securities Law"), and the interests have not been registered nor is there an intention to register them, under the Israeli Securities Law, or under the laws of any other jurisdiction. Investors in the interests will not be able to rely on such securities law in many matters related to or deriving from their investment in the Fund. The interests will be offered and sold under exemptions provided by the Israeli Securities Law in connection with the foregoing, therefore the offering and sale of securities in the Fund to investors that do not fall under the categories of Section 15a(b) of the Israeli Securities Law will be limited to 35 investors in any 12-month period. Neither the Israeli Securities Authority nor the regulatory authority of any other country, state or jurisdiction has approved or will approve this presentation or the interests referred to herein.
Any representation to the contrary is unlawful.

Neither the General Partner nor the management company, intend to register as an investment adviser, an investment marketer or an investment portfolio manager under the Israeli Regulation of Investment Advice, Investment Marketing and Investment Portfolio Management Law, 5755-1995, and neither of them carries insurance as set forth under the aforesaid laws. Nothing in this presentation constitutes legal, accounting or tax advice or individually tailored investment advice. It is further clarified that the interests in the Fund are not being registered under the U.S. Securities Act of 1933. The interests are being offered in a private placement and each investor will be required to make certain representations, including but not limited to (a) that it is an accredited investor as defined in Regulation D under the Securities Act, (b) that it is acquiring an interest in the Fund for its own account, for investment purposes only and not with a view to its distribution, and (c) that it has received or had access to all information it deems relevant to evaluate the merits and risks of the prospective investment. This presentation is not intended for, and does not constitute an offer to sell or the solicitation of an offer to buy, any interests in the Fund, to any person to whom such an offer or solicitation is unlawful or not authorized.

While we have endeavored to ensure that all data herein is accurate, no representation, express or implied, is made as to the accuracy, completeness or correctness of information contained in this presentation, including the accuracy, likelihood of achievement or reasonableness of any forecasts, prospects, returns or statements in relation to future matters contained in the presentation ("Forward Looking Statements"). Such Forward Looking Statements are by their nature subject to significant uncertainties and contingencies and are based upon a number of estimates and assumptions that are subject to change (and in many cases are outside the control of the Fund and its managers and general partner).

By participating in this presentation or by retaining a copy of this presentation, you agree to be bound by the foregoing limitations. This presentation (including all information contained herein) is being delivered on a confidential basis.

The presentation is the property of the Fund and no part of the presentation may be disclosed, distributed or reproduced to any third party without the consent of the Fund. The offering of interests in the Fund is a private offering and is not intended to constitute an "offer to the public" as defined in the Israeli Securities Law 5729-1968 (the "Israeli Securities Law"), therefore the offering and sale of securities in the Fund to investors that do not fall under the categories of Section 15a(b) of the Israeli Securities Law will be limited to 35 investors in any 12-month period. This presentation does not constitute an offer to invest in the Fund.

This document is issued by aMoon Ventures Y. SH. Ltd Company number 515563377 (aMoon) as a Corporate Authorised Representative (AR No. 001292024) of Polar 993 Advisory Pty Ltd (ACN 649 554 932) (AFSL 531197) (Polar Advisory). aMoon's authority under its Corporate Authorised Representative Agreement with Polar Advisory is limited to general advice regarding the aMoon Growth Fund II L.P. only to wholesale clients. This document is provided on a confidential, personal and private basis for use only by the recipient as a wholesale client under the Corporations Act 2001 (Cth) and should not be forwarded to others. The information contained in this document is of a general nature only and is not to be taken to contain any financial product advice or recommendation. Nothing in this document is intended as financial product advice and it does not take into account any person's investment objectives, financial circumstances or specific needs. This document is neither an offer to sell nor a solicitation of any offer to acquire interests or any other investment and should not be used as the basis for making an investment in the aMoon Growth Fund II L.P. aMoon and Polar Advisory and their directors, officers, employees, agents or associates do not guarantee repayment of capital, the performance of any fund or any service. Past performance is not a reliable indicator of future performance.

aMoon
ACCELERATING CURE